Martínez-Cuadrón, David http://orcid.org/0000-0001-7540-4091
Rodríguez-Macías, Gabriela
Rodríguez-Veiga, Rebeca
Boluda, Blanca
Montesinos, Pau
Funding for this research was provided by:
Daiichi Sankyo (Funding Daiichi Sankyo provided financial support for medical writing services.)
Article History
First Online: 7 January 2020
Compliance with Ethical Standards
:
: Daiichi Sankyo provided financial support for medical writing services.
: All patients gave written consent to take part in the study and the study was approved by the health authorities. The reference committee was the Ethical Committee of the Hospital Universitari i Politècnic La Fe, Valencia.
: David Martínez-Cuadrón has acted in an advisory role for JazzPharma, Novartis, Pfizer, Teva and Daiichi Sankyo; has served on the Speakers’ Bureau of Pfizer, Janssen, Amgen and Gilead; and has received travel grants from JazzPharma, Novartis, Pfizer and Amgen. Pau Montesinos has provided consultations or acted in an advisory role for JazzPharma, Novartis, AbbVie, Celgene, Shire, Takeda, Daiichi Sankyo, Pfizer, Tolero and Agios; has served on the Speakers’ Bureau of Otsuka, Novartis, AbbVie, Celgene, Incyte, Daiichi Sankyo and Pfizer; has received research funding from Novartis, Janssen, Celgene, Daiichi Sankyo, Pfizer and Teva; and has received travel grants from Teva, Novartis, Celgene, Daiichi Sankyo and Amgen. Rebeca Rodríguez-Veiga has served on the Speakers’ Bureau of Teva, Pfizer, Janssen and Novartis; and has received travel grants from Sanofi and Daiichi Sankyo. All other co-authors: nothing to disclose.